Q-omics provides the consensus-scored CCDC137 profile across patient tissues and cancer cell-line models. CCDC137 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCDC137 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, CCDC137 RNA expression shows 18,576 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where CCDC137 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC137 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC137 survival associations across molecular data types. CCDC137 RNA expression shows survival associations in the most cancer types (23), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC137 RNA expression–survival associations across cancer types. High CCDC137 expression shows unfavorable associations in KIRC, MESO, LIHC, ACC, KICH and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CCDC137 RNA expression.
This table summarizes CCDC137 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CCDC137. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC137 shows higher tumor expression in HNSC, KIRP, COAD, KIRC, BLCA and LIHC. The HNSC box plot shows higher CCDC137 RNA expression in tumor versus normal tissue (log2 FC = +0.882, t-test p < 0.001).
This table shows molecular features associated with CCDC137 in patient tissues and cancer cell lines. In patient samples, CCDC137 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC137 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
